np event 2254995 0E193A 1
Oct 16, 2024

Update on Emerging Anticoagulants

EARNed Credits

0.5

AMA PRA Category 1 CreditTM

CPE Contact Hour

CNE Contact Hour

iStock 1293132839

Cardiometabolic Medicine

The need for consistent updates and agile content is imperative for today’s clinician to remain current on the continuum of scientific data. In no therapeutic area is this more essential than in “Cardiometabolic Medicine,” a new term meant to encompass the interconnected and debilitating diagnoses of diabetes mellitus, heart failure, coronary artery disease/acute coronary syndrome, progressive renal insufficiency, and related disorders such as hypertension, hyperlipidemia, and hyperkalemia.  These areas are subject to frequent pivotal trial publications, guidelines updates, FDA action, and outcomes assessments.

Who Should Attend

Primary care physicians, internists, family medicine physicians, allied healthcare professionals and other healthcare providers.

Provided By

course faculty

Barnes e1713988045655
Geoffrey Barnes, MD, MSc
Associate Professor of Internal Medicine
Vascular and Cardiovascular Medicine
Director, Vascular Medicine Fellowship
Frankel Cardiovascular Center
University of Michigan
Ann Arbor, MI

Your only source for ACCREDITED SoMe-delivered serialized professional cardiometabolic education.

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Barnes e1713988045655
Geoffrey
Barnes

Review of Clinical Trial and Real-World Data for DOAC and other Anticoagulation Therapeutics for VTE

Consultant/Advisor: Abbott Vascular; Boston Scientific; Bristol-Myers Squib; Janssen; Pfizer
Board of Directors: Anticoagulation Forum

VTE and Anticoagulation - Guideline Updates for 2024

Consultant/Advisor: Abbott Vascular; Boston Scientific; Bristol-Myers Squibb; Janssen; Pfizer
Board of Directors: Anticoagulation Forum

Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC; Patrick Hayes and Nicole McMenamin hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM.

AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours.

AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of continuing pharmacy education credit.

Learners should only claim credit commensurate with the extent of their participation.

This activity has been supported by an independent educational grant from Anthos.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Anthos do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

  1. Read the accreditation information and faculty disclosures at the beginning of this activity.
  2. Read or Review the activity content.
  3. Complete the Post-Activity Test Questions and Evaluation.
  4. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact admin@academiccme.com.

np event 2254995 0E193A 1
Oct 16, 2024

Update on Emerging Anticoagulants

Related Tweetorial Courses

Group 39553
Cardiology
Early, Optimal Management of CKD and Cardiorenal Disease to Prevent Disease Progression an...